CN105727267A - 一种重组人透明质酸酶冻干制剂及其制备方法和应用 - Google Patents
一种重组人透明质酸酶冻干制剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN105727267A CN105727267A CN201610081945.XA CN201610081945A CN105727267A CN 105727267 A CN105727267 A CN 105727267A CN 201610081945 A CN201610081945 A CN 201610081945A CN 105727267 A CN105727267 A CN 105727267A
- Authority
- CN
- China
- Prior art keywords
- recombined human
- human hyaluronidase
- lyophilized formulations
- hyaluronidase
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000585728 Homo sapiens Protein O-GlcNAcase Proteins 0.000 title claims abstract description 53
- 102000046319 human OGA Human genes 0.000 title claims abstract description 53
- 229940101556 human hyaluronidase Drugs 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 238000004108 freeze drying Methods 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims abstract description 5
- 102000004190 Enzymes Human genes 0.000 claims abstract description 13
- 108090000790 Enzymes Proteins 0.000 claims abstract description 13
- 229940088598 enzyme Drugs 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 239000004094 surface-active agent Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 52
- 238000009472 formulation Methods 0.000 claims description 49
- 239000007788 liquid Substances 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002577 cryoprotective agent Substances 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000003223 protective agent Substances 0.000 claims description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 7
- 239000001110 calcium chloride Substances 0.000 claims description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000010254 subcutaneous injection Methods 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 206010018852 Haematoma Diseases 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 229960005015 local anesthetics Drugs 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 229940068977 polysorbate 20 Drugs 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 206010022086 Injection site pain Diseases 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 239000003636 conditioned culture medium Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract description 26
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 abstract description 26
- 229960002773 hyaluronidase Drugs 0.000 abstract description 26
- 102000008100 Human Serum Albumin Human genes 0.000 abstract description 8
- 108091006905 Human Serum Albumin Proteins 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 239000006172 buffering agent Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001012 protector Effects 0.000 abstract 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 8
- 229920002674 hyaluronan Polymers 0.000 description 8
- 229960003160 hyaluronic acid Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 5
- 229940044700 hylenex Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940054953 vitrase Drugs 0.000 description 2
- 241000561734 Celosia cristata Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108050009363 Hyaluronidases Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940042450 amphadase Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229940044734 hydase Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
操作步骤 | 设置板层温度(℃) | 保持时间(hr) | 设定真空度(mbar) |
(1)预冻 | -5 | 1.0 | |
(2)预冻 | -40 | 3 | |
(3)干燥 | -25 | 19.5 | 15 |
(4)干燥 | 0 | 2.0 | 15 |
(5)干燥 | 25 | 8.5 | 15 |
G | H | I | |
透明质酸酶 | 1800000IU | 1800000IU | 1800000IU |
吐温20 | 1.2g | 1.2g | 1.2g |
甘露醇 | 180g | 240g | 300g |
蔗糖 | 120g | 120g | 120g |
磷酸氢二钠 | 8.4g | 8.4g | 8.4g |
乙二胺四乙酸二钠 | 5.4g | 5.4g | 5.4g |
氯化钙 | 1.8g | 1.8g | 1.8g |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610081945.XA CN105727267B (zh) | 2016-02-05 | 2016-02-05 | 一种重组人透明质酸酶冻干制剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610081945.XA CN105727267B (zh) | 2016-02-05 | 2016-02-05 | 一种重组人透明质酸酶冻干制剂及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105727267A true CN105727267A (zh) | 2016-07-06 |
CN105727267B CN105727267B (zh) | 2020-05-26 |
Family
ID=56241921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610081945.XA Active CN105727267B (zh) | 2016-02-05 | 2016-02-05 | 一种重组人透明质酸酶冻干制剂及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105727267B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114010528A (zh) * | 2021-12-20 | 2022-02-08 | 广州栋方生物科技股份有限公司 | 一种重组人源胶原蛋白冻干粉及其制备方法 |
CN114250212A (zh) * | 2021-12-14 | 2022-03-29 | 华熙生物科技股份有限公司 | 一种透明质酸酶冻干制剂及其制备方法 |
EP4017524A4 (en) * | 2019-10-15 | 2022-09-21 | Standard of Care Corporation | COMPOSITIONS WITH HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT THEREOF |
US11723959B2 (en) | 2003-03-05 | 2023-08-15 | Halozyme, Inc. | Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1446912A (zh) * | 2003-03-14 | 2003-10-08 | 河北以岭医药研究院有限公司 | 一种重组葡激酶冻干制剂、制备方法和应用 |
CN103468662A (zh) * | 2013-09-29 | 2013-12-25 | 惠觅宙 | 一种重组人透明质酸酶、其生产纯化方法、制剂及使用方法与应用 |
CN104244968A (zh) * | 2011-12-30 | 2014-12-24 | 哈洛齐梅公司 | Ph20多肽变体、配制物及其应用 |
CN104768535A (zh) * | 2012-11-05 | 2015-07-08 | 株式会社Bmi韩国 | 用于透明质酸酶的稳定剂和包括透明质酸酶的液体制剂 |
-
2016
- 2016-02-05 CN CN201610081945.XA patent/CN105727267B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1446912A (zh) * | 2003-03-14 | 2003-10-08 | 河北以岭医药研究院有限公司 | 一种重组葡激酶冻干制剂、制备方法和应用 |
CN104244968A (zh) * | 2011-12-30 | 2014-12-24 | 哈洛齐梅公司 | Ph20多肽变体、配制物及其应用 |
CN104768535A (zh) * | 2012-11-05 | 2015-07-08 | 株式会社Bmi韩国 | 用于透明质酸酶的稳定剂和包括透明质酸酶的液体制剂 |
CN103468662A (zh) * | 2013-09-29 | 2013-12-25 | 惠觅宙 | 一种重组人透明质酸酶、其生产纯化方法、制剂及使用方法与应用 |
Non-Patent Citations (3)
Title |
---|
FROST G I. 等: ""Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration"", 《EXPERT OPINION ON DRUG DELIVERY》 * |
于忠喜: ""重组人生长激素冻干配方筛选和稳定性研究"", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
姚静等: "《药物冷冻制剂技术的设计与应用》", 30 June 2007, 北京:中国医药科技出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11723959B2 (en) | 2003-03-05 | 2023-08-15 | Halozyme, Inc. | Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide |
EP4017524A4 (en) * | 2019-10-15 | 2022-09-21 | Standard of Care Corporation | COMPOSITIONS WITH HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT THEREOF |
CN114250212A (zh) * | 2021-12-14 | 2022-03-29 | 华熙生物科技股份有限公司 | 一种透明质酸酶冻干制剂及其制备方法 |
CN114010528A (zh) * | 2021-12-20 | 2022-02-08 | 广州栋方生物科技股份有限公司 | 一种重组人源胶原蛋白冻干粉及其制备方法 |
CN114010528B (zh) * | 2021-12-20 | 2023-09-15 | 广州栋方生物科技股份有限公司 | 一种重组人源胶原蛋白冻干粉及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105727267B (zh) | 2020-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106620653B (zh) | 一种用于治疗皮肤创面的组合物及其制备方法 | |
CN105727267A (zh) | 一种重组人透明质酸酶冻干制剂及其制备方法和应用 | |
CN101095950B (zh) | 一种稳定的人用狂犬病疫苗冻干制剂及其制备 | |
CN106061503A (zh) | 液体稳定的猪病毒疫苗 | |
CN101209255B (zh) | 连翘酯苷注射制剂及其制备方法 | |
CA2378949C (en) | Growth hormone formulations | |
CN104906576B (zh) | 可供皮下注射的高浓度抗vegf抗体配制剂 | |
CN105797204A (zh) | 绿原酸在制备创伤敷料中的应用 | |
CN103655487B (zh) | 一种注射用前列地尔冻干乳剂 | |
CN111494611A (zh) | 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液 | |
CN104586899B (zh) | 一种治疗褥疮的气雾剂及其制备方法 | |
TWI649087B (zh) | 用於活減毒阿爾法病毒配方之組成物及方法 | |
CN102973922A (zh) | 一种融合蛋白的应用 | |
CN101693016A (zh) | 通用的注射用重组人血清白蛋白融合蛋白制剂配方 | |
KR20180135912A (ko) | 개선된 제형을 이용한 알파바이러스의 안정화 조성물 및 방법 | |
CN103948661B (zh) | 用于治疗妇科疾病、前列腺疾病或肛肠疾病的药物组合物及其应用 | |
US11077193B2 (en) | Nerve growth factor composition and powder injection | |
CN104888196A (zh) | 一种稳定的干扰素α多剂量笔注射液 | |
CN102327239A (zh) | 鲑鱼降钙素纳米脂质体注射剂及制备方法 | |
CN102526015A (zh) | 绿原酸在制备防治排卵障碍的药物或食品中的应用 | |
KR101095647B1 (ko) | 당단백질 호르몬 조성물 | |
CN102266298A (zh) | 一种培美曲塞二钠的药物组合物 | |
CN101333515A (zh) | 用dcik细胞培养的上清液及其应用 | |
US9987359B2 (en) | Subcutaneous injection product for cattle for inducing superovulation | |
CN1270761A (zh) | 大鲵高效催产剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210812 Address after: 215123 Room 401, C13 floor, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou, Jiangsu Province Patentee after: SUZHOU KANGJU BIOLOGICAL TECHNOLOGY Co.,Ltd. Patentee after: Shanghai Baoji Pharmaceutical Co.,Ltd. Address before: 215123 room 301A, C13 / F, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou City, Jiangsu Province Patentee before: SUZHOU KANGJU BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a lyophilized preparation of recombinant human hyaluronidase and a preparation method and application thereof Effective date of registration: 20211228 Granted publication date: 20200526 Pledgee: Shanghai Luocun Industrial Co.,Ltd. Pledgor: Shanghai Baoji Pharmaceutical Co.,Ltd. Registration number: Y2021980016793 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221031 Granted publication date: 20200526 Pledgee: Shanghai Luocun Industrial Co.,Ltd. Pledgor: Shanghai Baoji Pharmaceutical Co.,Ltd. Registration number: Y2021980016793 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
CP03 | Change of name, title or address |
Address after: 215123 room 301A, C13 / F, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou City, Jiangsu Province Patentee after: SUZHOU KANGJU BIOLOGICAL TECHNOLOGY Co.,Ltd. Patentee after: Shanghai Baoji Pharmaceutical Co.,Ltd. Address before: 215123 Room 401, C13 floor, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou, Jiangsu Province Patentee before: SUZHOU KANGJU BIOLOGICAL TECHNOLOGY Co.,Ltd. Patentee before: Shanghai Baoji Pharmaceutical Co.,Ltd. |
|
CP03 | Change of name, title or address |